Four women and three men after allogeneic (n ¼ 4) and autologous (n ¼ 3) haematopoietic SCT (HSCT) were observed to have an increase in T-cell large granular lymphocytes (T-LGLs) of CD3 þ CD8 þ phenotype for a median of 41 (15 --118) months. Clonal rearrangement of the T-cell receptor gene was verified by two PCR techniques and direct DNA sequencing, confirming that the cases were neoplastic and therefore classifiable as T-LGL leukaemia. In the allogeneic HSCT cases, T-LGL leukaemia was derived from donor T cells in three patients, as shown by DNA chimerism analysis, and recipient T cells in one patient who had graft failure previously. None of the patients showed cytopenia, autoimmune phenomenon or organ infiltration, which were features typical of de novo T-LGL leukaemia. Six patients had remained asymptomatic with stable large granular lymphocyte counts. One patient died from cerebral relapse of the original lymphoma. T-LGL leukaemias occurring post-HSCT are distinct from de novo T-LGL leukaemia and may have a different pathogenesis and clinical course. Patients did not require specific treatment, and the disease remained stable for long periods.
INTRODUCTION

T-cell large granular lymphocyte (T-LGL) leukaemia is a distinct clinicopathological entity as defined in the World Health
Organization (WHO) classification of lymphoid neoplasms. 1 It is characterized by a persistent (43 months) increase of large granular lymphocyte (LGL) count (42 Â 10 9 /L). Less commonly, cases with an LGL lymphocytosis of o2 Â 10 9 /L can still be diagnosed as T-LGL leukaemia if clonal rearrangement of the T-cell receptor (TCR) gene can be demonstrated. 1 Clonal rearrangement of the TCR gene also distinguishes T-LGL leukaemia from reactive T-LGL proliferation, which is often associated with underlying autoimmune diseases. 2 Occasionally, reactive T-LGL proliferations may in time develop into T-LGL leukaemia. 2 T-LGL leukaemia is a rare disease in the general population, with o400 cases believed to be ever reported. 3 Frequent clinical presentations include neutropenia, splenomegaly associated with rheumatoid arthritis in occidental patients, 3 and pure red cell aplasia in oriental patients. 4 The pathogenesis of T-LGL leukaemia remains undefined. However, chronic antigenic stimulation has been postulated to lead to polyclonal and eventually clonal proliferation of cytotoxic T cells. 3 Interestingly, this rare leukaemia has been reported to occur after both allogeneic and autologous haematopoietic SCT (HSCT). 5 --9 As only a few cases have been reported, the frequency, clinicopathological features and outcome of T-LGL leukaemia after HSCT are not well defined.
In this study, we investigated consecutive cases of T-LGL leukaemia that were diagnosed during 20 years in a cohort of HSCT patients.
MATERIALS AND METHODS Patients
At the HSCT clinic, patients who presented with an absolute lymphocytosis of 44 Â 10 9 /L for more than 3 months were examined by flow cytometry. Cases with a reversed CD4:CD8 ratio were fully immunophenotyped, and further investigated using PCR for TCR gene rearrangement. Cases confirmed to have clonal TCR gene rearrangement were diagnosed as T-LGL leukaemia and included in this analysis.
Morphological and immunophenotypical analysis
Morphological analysis was performed on Wright --Giemsa-stained blood and marrow smears. Immunophenotyping was performed with antibodies against a panel of T-cell-, B-cell-and natural killer-cell-associated Ags 10 by standard flow cytometric methods.
Molecular analysis
PCR for TCR gene rearrangement was performed by two methods. Initially, multiplex PCR with two groups of fluorescence-labelled primers was performed. The first group of primers consisted of three sets of primers for the TCR-gamma (TCRG) gene (Vg consensus, Jp and Jg). 11 The second group consisted of six sets of BIOMED-2 primers, including three sets of primers for the TCR-beta (TCRB) gene, two sets of primers for the TCRG gene and one set of primers for the TCR-delta (TCRD) gene.
12 PCR products were analyzed by automated capillary electrophoresis. For samples showing clonal peaks, the TCRG gene was further amplified by conventional PCR 5 to doubleconfirm clonality. The resulting clonal PCR product was gel purified and directly sequenced in both directions. DNA chimerism analysis was performed for patients undergoing allogeneic HSCT by a semi-quantitative PCR for polymorphic STR sequences with fluorescence-labelled primers as reported. 13 
RESULTS
Patients
In a 20-year period, among 1675 consecutive cases of HSCT (allogeneic, n ¼ 1246; autologous, n ¼ 429), eight patients with T-LGL leukaemia were identified. Therefore, the frequency of T-LGL leukaemia in our cohort was 0.5%. One patient had previously been reported 5 and hence was omitted from this analysis. The clinicopathological features of the other seven cases were shown in Table 1 .
Clinical presentation
Patients were asymptomatic when lymphocytosis was detected. Anaemia and/or thrombocytopenia were detected in three cases, all in the early stages after haematopoietic engraftment (3 --6 months). On follow-up, the cytopenias gradually resolved despite the persistence of T-LGL lymphocytosis, suggesting that the initial cytopenias were related to instability of the haematopoietic engraftment during the early stages of HSCT, rather than haematopoietic suppression mediated by the T-LGL leukaemic cells. At a median follow-up of 41 (15 --118) months after the diagnosis of T-LGL leukaemia, six of seven patients were alive with stable LGL counts and no relevant symptoms (Table 2 ).
Risk factors for T-LGL leukaemia
The primary diagnoses ranged from chronic and acute leukaemia to aggressive lymphoma and myeloma. No common HSCT-related problems were observed in the seven cases. After the diagnosis of T-LGL leukaemia, no specific complications were observed. Hence, no apparent risk factors for the development of T-LGL leukaemia could be identified.
Morphological and immunophenotypical analysis All seven cases showed a persistent LGL lymphocytosis (Figure 1) . Immunophenotypically, six cases were CD2 þ , CD3 þ , CD4--, CD5 þ , CD7 þ and CD8 þ , and expressed TCRab ( Figure 1 ) ( Table 3) . None of the cases were positive for natural killer-cell-associated In two patients (cases 3 and 5), TCRB, TCRG and TCRD genes were all clonally rearranged. In three patients (cases 1, 4 and 6), only the TCRG gene could be shown to be rearranged, whereas in one case (case 2), TCRB and TCRD but not TCRG genes were rearranged. In case 7, the BIOMED-2 primers failed to give a clonal product. However, PCR for TCRG showed a clonal product. To further confirm the TCR gene rearrangement, the TCRG gene was amplified and clonal PCR products were sequenced. Direct DNA sequencing confirmed clonal rearrangement at the VNJ region in six cases (Table 3) . In case 2, where TCRG could not be shown to be rearranged with the TCRG and BIOMED-2 TCRG primers employed, DNA sequencing could not be performed.
Origin of T-LGL leukaemia
For the four cases undergoing allogeneic HSCT, three patients (cases 1 --3) were shown to have exclusively donor DNA chimerism, therefore indicating that the T-LGL leukaemia was of donor origin (Table 2) . However, donor cells failed to engraft in one patient (case 4) after the matched unrelated donor HSCT, so that circulating cells were exclusively recipient in origin. Thus, the T-LGL leukaemia was recipient in origin.
Outcome and long-term follow-up For the allogeneic HSCT group, three of four patients (cases 1, 3 and 4) could be considered high-risk cases for disease relapse. Cases 1 and 4 had failed multiple previous chemotherapies and autologous HSCT, and even an allogeneic HSCT from an HLAmatched sibling. Case 3 was transplanted with disease only in PR. At a median follow-up of 72 (25 --117) months, all patients had remained in remission. For the autologous HSCT group, one patient had died of a cerebral relapse. Two patients were alive. Case 6 had CML with no detectable BCR-ABL1. Case 7 had stable minimal residual myeloma, with a paraprotein of about 3/dL.
DISCUSSION
We described the largest series of T-LGL leukaemia post-HSCT to date. An obvious contention is whether these cases should be classified as T-LGL leukaemia. All cases fit the WHO diagnostic criteria for T-LGL leukaemia, with expansion of CD8 þ LGL to 42 Â 10 9 /L for more than 3 months. In order to ensure that these T-LGLs were clonal and therefore neoplastic, we used two different PCR techniques to detect clonal TCR gene rearrangement. The PCR amplification products were sequenced to prove clonality. The results firmly established that in all cases, clonal proliferation of LGLs was found. Hence, the most appropriate diagnosis was T-LGL leukaemia, in the absence of other established diagnostic labels.
T-LGL leukaemias occurring de novo are usually diagnosed in patients with abnormal blood counts or symptoms. Presenting problems in Western patients include neutropenia (62%), anaemia (47%), splenomegaly (40%), recurrent infections (30%) and rheumatoid arthritis (27%). In Asian patients, anaemia (60%) and pure red cell aplasia (47%) were more common. 4 However, none of our cases showed these clinical features. Patients were asymptomatic. There were no associated cytopenias or autoimmune phenomena typically found in de novo T-LGL leukaemia. 14 The LGL counts had remained stable for long periods, up to ten years in one patient, without evidence of disease progression or organ infiltration. Therefore, although the diagnosis as stipulated by WHO criteria was T-LGL leukaemia, the clinical presentation was different from de novo T-LGL leukaemia, 1 --4 suggesting that a different pathological process might be involved.
Interestingly, non-neoplastic expansion of CD8 þ LGL has been described after allogeneic HSCT. In an earlier study, increase in CD8 þ LGL was found to occur as early as 3 months post-HSCT, which was significantly associated with CMV infection. 15 However, there were no related haematopoietic disturbances and the patients were asymptomatic. These observations were later validated in another series, where CD8 þ LGL expansion was seen between 3 --15 months after allogeneic HSCT, also in the context of increased CMV infection. 16 Different from the earlier study, however, the patients presented with mild to severe cytopenia, and autoimmune manifestations including polyarthritis and hypergammaglobulinaemia. The most important feature that distinguishes these reports from our study is that all their cases involved polyclonal T-cell proliferations, so that the LGL expansion was reactive and not neoplastic.
On the other hand, isolated cases of clonal T-LGL proliferation post-HSCT have been reported. showed, in addition to a patient described by us, 5 five other reported cases after both autologous and allogeneic HSCT (Table 4) . In allogeneic HSCT, the T-LGLs were shown to be donor in origin. In all but two cases, patients were asymptomatic without evidence of a leukaemic process. In the two patients who had a fatal outcome, death was attributable to GVHD and sepsis in one case, and respiratory failure in the other case. 5, 9 These findings were remarkably similar to the seven patients in our series, in that the majority of cases showed an indolent course that did not require specific treatment.
The presence of a persistent clonal LGL proliferation indicated that our cases were neoplastic. However, it must be noted that neoplastic T-LGL proliferations are not always symptomatic. The term 'T-cell clonopathy of undetermined significance' had once been proposed. 17 Although this condition had never become a diagnostic entity, later studies appeared to confirm that some cases of clonal T-LGL proliferation might be indolent and not necessarily associated with cytopenias and autoimmune manifestations. 18 The LGL proliferations in our series affected both autologous and allogeneic cells, suggesting that neoplastic transformation was related to post-HSCT predispositions rather than an inherent problem with the CD8 þ T-lymphocytes. Although initial reports of polyclonal T-LGL proliferations implicated CMV reactivation as a related factor, 14,15 subsequent reports were unable to establish a definite relationship with CMV infection, because CMV reactivation was such a common event post-HSCT. In this series, a consistent association with a post-HSCT complication could not be observed. EBV is another infectious agent that may be associated with T-cell lymphoproliferative diseases. However, because EBV is typically absent in de novo T-LGL leukaemia, 4 it was not sought in our patients.
Earlier studies on polyclonal T-LGL proliferations reported a favourable outcome of the original malignancies, suggesting that the LGL might mediate a graft vs malignancy effect.
14,15 Three of our four allogeneic HSCT recipients were high-risk cases, with transplantation performed for refractory or relapsed malignancies. Whether the favourable outcome of our cases was indeed related to the LGL proliferation remains to be defined.
The frequency of T-LGL leukaemia in this cohort of post-HSCT patients was 0.5%. T-LGL leukaemia has also been described as a post-transplantation T-cell lymphoproliferative disease after renal allografting. 19 In an earlier study of three such cases, two patients had asymptomatic LGL lymphocytosis only. 19 Later studies using PCR for TCR gene rearrangement reported a much higher frequency of clonal T-cell proliferation (44 --71%) in renal and cardiac allograft recipients. 20 However, none of these cases showed a persistent LGL lymphocytosis, making it doubtful that these were really neoplastic T-cell proliferations. Therefore, the incidence of clonal CD8 þ T-LGL lymphoproliferation in other organ transplantations remains to be defined.
To conclude, T-LGL leukaemias occurring post-HSCT may have a different pathogenesis and clinical course as compared with de novo T-LGL leukaemias. Patients often remain stable for years and do not require specific treatment. Finally, although T-LGL leukaemia was the diagnosis based on WHO criteria, patients in this series were only aware of the lymphocytosis, but not the pathological diagnosis. Before this condition is better defined by studying more cases, it may be prudent to be discreet with disclosure of the pathological diagnosis, in view of the psychological gravity that a diagnosis of leukaemia might impose on patients who have already undergone an HSCT for another haematological malignancy.
